Skip to content

Study · Animal study (in vivo) · mouse · 2019

6 results

A PepT1 mediated medicinal nano-system for targeted delivery of cyclosporine A to alleviate acute severe ulcerative colitis.

Wu Y, Sun M, Wang D, Li G, Huang J, Tan S, Bao L, Li Q, Li G, Si L

Biomaterials science13 Aug 2019Cited by 42 (Europe PMC)

PMID31408067 (opens in a new tab)DOI10.1039/c9bm00925f (opens in a new tab)PepBankPUB-31408067
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with DSS-induced ulcerative colitis, KPV nanoparticles without cyclosporine A also showed marked therapeutic effects.

    In plain wordsIn mice with colitis, nanoparticles with KPV but without cyclosporine A also showed clear treatment effects.

    Peptide
    KPV
    Outcome
    Not applicableTherapeutic effect of KPV nanoparticles without CyA
    Study

    mousen: not reported in source

    DSS-induced ulcerative colitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Intriguingly, PKMCN without CyA also presented marked therapeutic effects.
    2 context sentences
    Summary · context
    After being treated with the CyA-PLGA-KPV/MMT/CS nanoparticles (PKMCN), the mice with DSS-induced ulcerative colitis exhibited significant improvements in body weight, colon length, and disease activity index.
    Summary · context
    To effectively alleviate acute severe ulcerative colitis (ASUC), we developed a colon-specific delivery system-PLGA-KPV/MMT/CS multifunctional medicinal nanoparticles loaded with cyclosporine A (CyA).

Studies that did not test the peptide alone5

In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking KPV.

  1. 02AnimalNot a test of KPV aloneAnimal study (in vivo)Pharmacokinetics

    KPV-containing nanoparticles accumulated specifically in inflamed tissues and were retained for up to 36 h.

    In plain wordsIn animals, nanoparticles with KPV gathered in inflamed tissue and stayed there for up to 36 hours.

    Peptide
    KPV
    Outcome
    Not applicableNanoparticle accumulation and retention in inflamed tissue
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Gastrointestinal

    Measurements

    retention time
    ≤ 36 h
    inflamed tissues

    Source sentences

    Summary
    The bio-distribution demonstrated that nanoparticles can specifically accumulate in the inflamed tissues and can be retained for up to 36 h.
    1 context sentence
    Summary · context
    To effectively alleviate acute severe ulcerative colitis (ASUC), we developed a colon-specific delivery system-PLGA-KPV/MMT/CS multifunctional medicinal nanoparticles loaded with cyclosporine A (CyA).

    In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.

  2. 03AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome

    In mice with DSS-induced ulcerative colitis, CyA-loaded KPV nanoparticles (PKMCN) improved body weight.

    In plain wordsIn mice with colitis, nanoparticles carrying KPV and cyclosporine A improved body weight.

    Peptide
    KPV
    Outcome
    IncreaseBody weight
    Study

    mousen: not reported in source

    DSS-induced ulcerative colitis
    Outcome group
    Body weight · Gastrointestinal

    Source sentences

    Summary
    After being treated with the CyA-PLGA-KPV/MMT/CS nanoparticles (PKMCN), the mice with DSS-induced ulcerative colitis exhibited significant improvements in body weight, colon length, and disease activity index.
    1 context sentence
    Summary · context
    To effectively alleviate acute severe ulcerative colitis (ASUC), we developed a colon-specific delivery system-PLGA-KPV/MMT/CS multifunctional medicinal nanoparticles loaded with cyclosporine A (CyA).

    In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.

  3. 04AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome

    In mice with DSS-induced ulcerative colitis, CyA-loaded KPV nanoparticles (PKMCN) improved colon length.

    In plain wordsIn mice with colitis, nanoparticles carrying KPV and cyclosporine A improved colon length.

    Peptide
    KPV
    Outcome
    IncreaseColon length
    Study

    mousen: not reported in source

    DSS-induced ulcerative colitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    After being treated with the CyA-PLGA-KPV/MMT/CS nanoparticles (PKMCN), the mice with DSS-induced ulcerative colitis exhibited significant improvements in body weight, colon length, and disease activity index.
    1 context sentence
    Summary · context
    To effectively alleviate acute severe ulcerative colitis (ASUC), we developed a colon-specific delivery system-PLGA-KPV/MMT/CS multifunctional medicinal nanoparticles loaded with cyclosporine A (CyA).

    In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.

  4. 05AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome

    In mice with DSS-induced ulcerative colitis, CyA-loaded KPV nanoparticles (PKMCN) improved the disease activity index.

    In plain wordsIn mice with colitis, nanoparticles carrying KPV and cyclosporine A improved the disease activity score.

    Peptide
    KPV
    Outcome
    DecreaseDisease activity index
    Study

    mousen: not reported in source

    DSS-induced ulcerative colitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    After being treated with the CyA-PLGA-KPV/MMT/CS nanoparticles (PKMCN), the mice with DSS-induced ulcerative colitis exhibited significant improvements in body weight, colon length, and disease activity index.
    1 context sentence
    Summary · context
    To effectively alleviate acute severe ulcerative colitis (ASUC), we developed a colon-specific delivery system-PLGA-KPV/MMT/CS multifunctional medicinal nanoparticles loaded with cyclosporine A (CyA).

    In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.

  5. 06AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome

    In mice with colitis, biochemical and immunohistochemical readouts in the PKMCN group were as good as in the healthy group.

    In plain wordsIn mice with colitis, lab markers after treatment with the nanoparticles were as good as in healthy mice.

    Peptide
    KPV
    Outcome
    No significant changeBiochemical and immunohistochemical markers versus healthy group
    Study

    mousen: not reported in source

    DSS-induced ulcerative colitis
    Comparator
    Healthy group
    Outcome group
    Inflammation markers · Gastrointestinal

    Source sentences

    Summary
    Moreover, biochemistry and immunohistochemical analysis showed that the PKMCN treatment group performed as well as the healthy group.
    2 context sentences
    Summary · context
    After being treated with the CyA-PLGA-KPV/MMT/CS nanoparticles (PKMCN), the mice with DSS-induced ulcerative colitis exhibited significant improvements in body weight, colon length, and disease activity index.
    Summary · context
    To effectively alleviate acute severe ulcerative colitis (ASUC), we developed a colon-specific delivery system-PLGA-KPV/MMT/CS multifunctional medicinal nanoparticles loaded with cyclosporine A (CyA).

    In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.